Evidence map›Paper›PMID 42186470›Full record

ReviewYonago acta medica2026

Current Understanding of Circulating Apolipoprotein E-Containing High-Density Lipoproteins and Their Clinical Utility in Cardiovascular Disease Risk Assessment.

Shinichi Usui

Abstract readReview
In one paragraph

Review in Yonago acta medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Shinichi UsuiDepartment of Pathobiological Science and Technology, School of Health Science, Faculty of Medicine, Tottori University, Yonago 683-8503, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plasma high-density lipoprotein (HDL) plays a key role in transporting accumulated excess cholesterol from the peripheral tissues to the liver, and has other multiple cardioprotective functions, including antioxidant, anti-inflammatory, and antithrombotic effects. However, HDL-cholesterol (HDL-C) levels, which are commonly measured in a clinical testing, may not necessarily reflect the beneficial aspects of HDLs. In fact, recent studies have shown that increasing HDL-C with medication does not reliably prevent cardiovascular disease. Furthermore, recent advances in proteomic technology have revealed hundreds of proteins associated with HDLs, which contribute to their structural heterogeneity and functional diversity. Accordingly, identifying specific HDL family members is useful in assessing cardiovascular disease risk, rather than evaluating HDL as a single family. Certain HDLs contain apolipoprotein E (apoE), which plays an important role in cholesterol transport. However, our understanding of apoE-containing HDL (apoE-HDL) has become complex as apoE-HDL is a heterogeneous population that differs in particle compositions and sizes, as well as biological functions. This review focuses on apoE-HDL and summarizes its characteristics and functions as well as the clinical significance of its measurement, discussing its potential as a novel biomarker for cardiovascular disease risk assessment.

Indexed as

apolipoprotein Eatherosclerosiscardiovascular diseasehigh-density lipoproteinsubclass

Identifiers

PMID42186470
PMCPMC13198964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.